Q4 2025 Bausch Health Companies Inc Earnings Call Transcript
Key Points
- Bausch Health Companies Inc (BHC) achieved its 11th consecutive quarter of growth in both revenue and adjusted EBITA, reflecting consistent performance.
- The company reported a 9% increase in revenue on a reported basis and a 5% increase on an organic basis for the fourth quarter, excluding Bausch & Lomb.
- BHC successfully acquired Shibo, a full-service aesthetics distribution platform in China, enhancing its commercial presence in a key market.
- The company reduced its net debt by several hundred million dollars and improved its debt maturity profile by approximately $1.7 billion through a debt exchange.
- BHC's Salix and Salta segments delivered double-digit top-line growth of 11% and 18% respectively, highlighting the diversification of the portfolio.
- The adjusted gross margin decreased by 80 basis points compared to the same period a year ago.
- Adjusted operating cash flow for the fourth quarter was down $205 million year over year, primarily due to changes in timing of cash interest payments.
- The company's Red Sea trials did not meet their primary endpoints, leading to a review of potential new development opportunities.
- Canada's revenue contracted by 6% due to increased generic competition for Wellbutrin.
- The Salta medical segment experienced a slight decrease in revenue due to the transition of a full-service distributor in China.
Greetings and welcome to the Busch Health Fourth quarter and full year 2025 earnings conference call and webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow a formal presentation. You will be placed in the question queue at anytime by pressing 1 on your telephone keypad.
We ask you ask one question, one follow-up, and return to the queue.
As a reminder, this conference is being recorded.
If anyone should require operator assistance, please press 0. It's not my pleasure to turn the call over to your host, Karen Sarafian, Vice President of Investor relations. Karen, please go ahead.
Good afternoon and welcome to Buschal's 4th quarter and full year 2025 earnings conference call. My name is Garen Sarafian, Vice President of Investor relations.
Participating in today's call are Thomas Ao, Chief Executive Officer, JJ Sharon, Chief Financial Officer, and Jonathan Sade, Chief Medical Officer
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
